Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling

Moll, J. Matthijs; Hofland, Johannes; Teubel, Wilma; Ridder, Corina M.A. De; Taylor, Angela; Graeser, Ralph; Arlt, Wiebke; Jenster, Guido; Van Weerden, Wytske

DOI: 10.1002/pros.24297

License: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Moll, JM, Hofland, J, Teubel, W, Ridder, CMAD, Taylor, A, Graeser, R, Arlt, W, Jenster, G & Van Weerden, W 2022, 'Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling', The Prostate, vol. 82, no. 5, pp. 505-516. https://doi.org/10.1002/pros.24297

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- Users may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (7)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 29. Sep. 2023
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling

J. Matthijs Moll MD | Johannes Hofland MD, PhD | Wilma J. Teubel | Corina M. A. de Ridder | Angela E. Taylor PhD | Ralph Graeser PhD | Wiebke Arlt MD DSc FRCP FMedSci | Guido W. Jenster PhD | Wytske M. van Weerden PhD

1Department of Urology, Erasmus MC, Rotterdam, The Netherlands
2Department of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
3Centre for Endocrinology, Diabetes and Metabolism (CEDAM), School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK
4Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA

Abstract

Introduction: Castration-resistant prostate cancer (CRPC) remains dependent on androgen receptor (AR) signalling, which is largely driven by conversion of adrenal androgen precursors lasting after castration. Abiraterone, an inhibitor of the steroidogenic enzyme CYP17A1, has been demonstrated to reduce adrenal androgen synthesis and prolong CRPC patient survival. To study mechanisms of resistance to castration and abiraterone, we created coculture models using human prostate and adrenal tumours.

Materials and Methods: Castration-naïve and CRPC clones of VCaP were incubated with steroid substrates or cocultured with human adrenal cells (H295R) and treated with abiraterone or the antiandrogen enzalutamide. Male mice bearing VCaP xenografts with and without concurrent H295R xenografts were castrated and treated with placebo or abiraterone. Response was assessed by tumour growth and PSA release. Plasma and tumour steroid levels were assessed by LC/MS-MS. Quantitative polymerase chain reaction determined steroidogenic enzyme, nuclear receptor and AR target gene expression.

Results: In vitro, adrenal androgens induced castration-naïve and CRPC cell growth, while precursors steroids for de novo synthesis did not. In a coculture system, abiraterone blocked H295R-induced growth of VCaP cells. In vivo, H295R promoted castration-resistant VCaP growth. Abiraterone only inhibited VCaP growth or PSA production in the presence of H295R. Plasma steroid levels demonstrated CYP17A1 inhibition by abiraterone, whilst CRPC tumour tissue steroid levels showed no evidence of de novo intratumoural androgen production. Castration-resistant and abiraterone-resistant VCaP tumours had increased levels of AR, AR variants and...
glucocorticoid receptor (GR) resulting in equal AR target gene expression levels compared to noncastrate tumours.

**Conclusions:** In our model, ligand-dependent AR-regulated regrowth of CRPC was predominantly supported via adrenal androgen precursor production while there was no evidence for intratumoural androgen synthesis. Abiraterone-resistant tumours relied on AR overexpression, expression of ligand-independent AR variants and GR signalling.

**Keywords**
abiraterone, adrenal androgens, androgen synthesis, AR variants, castration resistant prostate cancer, CYP17A1 inhibition, glucocorticoid receptor, xenograft

1 | INTRODUCTION

Androgen receptor (AR) reactivation is a major driver of castration-resistant prostate cancer (CRPC) and the majority of CRPC tumours remain AR dependent. A substantial proportion of CRPC tumours contain equal amounts of 5α-dihydrotestosterone (DHT) compared to tumours growing in noncastrate hosts. It has been generally accepted that CRPC tissue can generate its own androgens via conversion of the adrenal precursor steroids dehydroepiandrosterone (DHEA) and androstenedione into DHT, with CRPC tumours abundantly expressing markers for these conversions. More controversially, preclinical CRPC models have been reported to possess the potential for de novo androgen synthesis from cholesterol.

Advances were made in the hormonal treatment of CRPC by the introduction of the steroid synthesis inhibitor abiraterone [Zytiga®]—which blocks synthesis of the testosterone precursor DHEA via CYP17A1 inhibition—and the antiandrogen enzalutamide [Xtandi®].

Multiple mechanisms leading to resistance to second-line hormonal therapies have been described. Resistance to abiraterone and enzalutamide has been linked to increased intratumoural androgen synthesis via the classical or the alternative synthesis pathway. Mutations in the ligand-binding domain and overexpression of the AR allowing promiscuous binding of the AR to steroids other than the classical androgens (e.g., progestens or glucocorticoids) have been described for abiraterone and enzalutamide. In addition, AR amplification and expression of ligand-independent AR variants have been associated with resistance to abiraterone and enzalutamide. Also, increased glucocorticoid receptor (GR) signalling, taking over part of the transcriptional program of the AR, has been described as a mechanism for primary and secondary resistance to both castration and enzalutamide. In patient derived xenografts, GR expression was elevated in tumours with intrinsic and acquired resistance to abiraterone treatment.

However, preclinical research is hampered by significant differences in adrenal steroid biology between humans and rodents. Although we and others found little evidence of CYP17A1-dependent adrenal steroid synthesis in castrate rodents, some reports have reported minimal production of androgens in murine adrenal glands after castration.

Interestingly, however, in these models CRPC tumours were less affected by treatment with abiraterone than by adrenalectomy, questioning an accurate, druggable, representation of human endocrine biology that likely supports CRPC. In this study, we developed in vitro and in vivo coculture models of prostate cancer with human adrenal cells to show that ligand-dependent AR activation in CRPC depends predominantly on androgen precursors secreted by the adrenal gland. Upon abiraterone treatment alternative steroid synthesis pathways, ligand-independent AR (variant) expression and GR expression may subsequently determine drug resistance.

2 | MATERIALS AND METHODS

2.1 | Cell culture

VCaP and VCaP CRPC subclones (DCC-E, BIC-B, FLU-D) cells were cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS) or steroid dextran-coated charcoal stripped FCS (DCC) with or without addition of 1 µM antiandrogen for CRPC clones and antibiotics. H295R cells—a human adrenocortical tumour cell line which expresses CYP17A1 and subsequently produces high amounts of DHEA and androstenedione—were grown in DMEM/F12, supplemented with 5% FCS and antibiotics. For growth experiments, 5 × 10³ VCaP cells were plated in 96-well culture plates (Corning) in RPMI supplemented with 10% dextran-coated charcoal stripped FCS (DCC) and antibiotics and left to attach overnight. Cultures were incubated with steroids similar at serum levels found in 60-year-old men and men undergoing ADT with 0.1 nM DHT as a positive control based on our experiences in quadruplicate (Table S1). After 10 days, cell numbers were measured by MTT (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)- assay (Sigma) as published in, with each experiment performed in triplicate. For coculture experiments, 5 × 10⁴ VCaP cells were plated in 24-well culture plates (Corning) and in parallel, 1 × 10⁴ H295R cells were plated in 24 well culture inserts with 0.4 µm pores (Corning), both in RPMI supplemented with 10% DCC and antibiotics. After separate overnight attachment, cultures were combined and incubated with indicated
compounds and left to grow for 9 days, after which cell number was assessed by MTT assay for each separate compartment, with each condition in duplicate.

2.2 | Animal studies

All animal studies were performed in accordance with local animal welfare legislation and with permission of the local animal experimentation ethics committee. Intact male NMRInu/nu mice were subcutaneously inoculated with 5 × 10^6 VCaP cells in 100 µl matrigel (BD Biosciences) with or without concurrent injection of 5 × 10^6 H295R cells in PBS in the contralateral flank (+ADR→ORx). Tumour volume (TV) was measured twice a week using callipers and estimated by [(height × width)^2] × 0.5236. At VCaP TV >150 mm^3, animals bearing only VCaP tumours were randomly assigned to sham castration (intact), castration with or without concomitant H295R inoculation (ORx + ADR and ORx, respectively) and all +ADR→ORx animals were castrated. Orchiectomy was surgically performed under isoflurane anaesthesia. When tumours progressed after castration (defined as a twofold increase in tumour volume after castration), animals were fed daily with 20% HP cyclodextrin (Sigma), adjusted to pH 4.0 (vehicle) or vehicle with 10 mg/ml abiraterone acetate (kindly provided by Janssen, Beerse, Belgium) to reach a final dose of 175 mg/kg. At indicated time points, 50 µl blood was drawn via mandibular puncture and stored at −80°C until further use. When single tumour volume reached >1500 mm^3 or combined TV was >2500 mm^3, animals were anaesthetised and blood was drawn via orbital bleeding, after which animals were euthanized. Blood and tumours were snap frozen and stored at −80°C until further use, with a part of each tumour stored separately in paraffin.

2.3 | PSA response

Blood was collected in heparin tubes and plasma was separated by centrifugation at 1500g for 5 min. PSA was quantified by enzyme-linked immunoassay, using the Elecsys total PSA immunoassay on a Cobas e602 analyzer (Roche Diagnostics). PSA response after castration was calculated as the % increase or decrease versus that of PSA at time of treatment initiation.

2.4 | Messenger RNA (mRNA) expression analysis

RNA was isolated using RNA-Be (TEL-TEST, Inc.) from frozen tumour pieces. Reverse transcriptase and quantitative polymerase chain reaction (qPCR) runs were performed as described previously by multiplying the fraction of AR positive cells with the staining intensity (0 = no staining, 1 = nuclear, 2 = nuclear + cytoplasmic), GR staining was scored as the percentage of positive cells per field at ×20 magnification.

Steroids were extracted from 200 µl of murine plasma or xenograft tissues homogenized in 1 ml milliQ using an Ultra-Turrax T25 (IKA). Following the addition of deuterated steroid controls, liquid-liquid extraction of steroids was performed using tert-butyl-methyl-ether (Sigma-Aldrich). The organic phase was removed after vortexing and evaporated under N₂ at 55°C. Samples were reconstituted in 50/50 methanol/water and analysed by liquid chromatography/tandem mass spectrometry (LC-MS/MS) employing a Waters Xevo mass spectrometer with Acquity uPLC system according to conditions previously described. Steroids were identified through matching retention times and two mass transitions relative to authentic steroid standards. Quantification was performed relative to a calibration series (range: 0.5–500 ng/ml).

2.6 | Immunohistochemistry

Formalin-fixed paraffin embedded tumour pieces were cut, and stained with haematoxylin-eosin. Vital tumour areas were selected for TMA construction with two cores included from each individual tumour. TMA slides were dewaxed, rehydrated, and blocked for endogenous peroxidase activity. Antigen retrieval was performed in sodium citrate buffer (pH 6.0) for 15 min at 100°C. Antibodies against AR (SP107, 1:200; Spring Bioscience) and GR (611227, 1:500; BD Transduction Laboratories) were diluted in normal antibody diluent (Immunologic) and incubated overnight at 4°C. Detection of antigens was performed using the DAKO REAL Envision Rabbit/Mouse HRP kit (DAKO) according to standard manufacturer's protocol, after which slides were counter stained with haematoxylin. Images were taken with an Olympus BX41TF microscope equipped with an Olympus Colorview IIlu camera (Olympus). AR expression was quantified by multiplying the fraction of AR positive cells with the staining intensity (0 = no staining, 1 = nuclear, 2 = nuclear + cytoplasmic). GR staining was scored as the percentage of positive cells per field at ×20 magnification.
2.7 | Statistical analysis

Raw data (TV, serum PSA, PSA response) were compared with the appropriate nonparametrical tests. MTT data were analysed by a one-way analysis of variance (ANOVA), followed by a Bonferroni corrected post hoc test to assess significant growth induction by steroids and inhibition by abiraterone and enzalutamide per steroidal condition. qPCR results levels were log10 transformed to normalize for difference in variance and subsequently compared using a one-way-ANOVA with a Bonferroni posttest. Survival curves were analysed using the Log-rank Test. Endpoint for progression-free survival (PFS) after castration was a fivefold increase in tumour volume (mean + 800 mm³), censoring animals started on abiraterone before this endpoint was met. Endpoint for PFS after treatment with abiraterone or placebo was a twofold increase in tumour volume (mean + 450 mm³), censoring animals that were euthanized before this endpoint was met. Growth rates were fitted on the %growth for each individual tumour using an exponential growth curve with $Y = 100\times 100^ {x/t}$ where $Y$ is the %TV, $x$ is the days postintervention and $k$ is the tumour dependent variable defining the steepness of the curve, correlating to growth rate. All statistical analyses and graphs were made using Graphpad Prism 9.0.

3 | RESULTS

3.1 | Castration-naïve and CRPC VCaP cell lines are stimulated by physiological levels of adrenal androgens

VCaP cells were incubated with testosterone precursor steroids to test the proliferative effects of physiological steroid levels found in prostate cancer patients (Table S1). CYP17A1 substrates pregnenolone and progesterone failed to induce castration-naïve parental VCaP proliferation (Figure 1A). In contrast, adrenal androgens DHEA and androstenedione induced growth comparable to DHT, which was abolished by direct AR antagonism with 1 µM enzalutamide, but not by 0.1 µM abiraterone. The abiraterone concentration of 0.1 µM was chosen to allow efficient CYP17A1 inhibition, while limiting the direct anti-androgen effect of abiraterone, observed at concentrations >1 µM. A similar response was observed for the VCaP CRPC clones DCC-E, BIC-B and FLU-D (Figure 1A). Of note, VCaP parental cells treated with vehicle did not divide during the 10-day incubation period, while DCC-E, BIC-B and FLU-D multiplied 3-fold. This growth was unaffected by CYP17A1 inhibition by abiraterone.

3.2 | Human adrenal tissue drives castration-resistant growth of VCaP, which can be blocked by CYP17A1 inhibition

To simulate the endocrine system present in men under ADT, human adrenal H295R cells were cocultured with parental and CRPC VCaP cells. H295R stimulated VCaP growth (Figure 1B) similar to DHT. Addition of 0.1 µM abiraterone reduced the H295R-induced proliferation of castration-naïve VCaP and its CRPC clone DCC-E, while not affecting proliferation of VCaP monocultures.

To take this further, we inoculated parental hormone-naïve VCaP cells in intact NMRI nu/nu mice whilst simultaneously inoculating H295R cells contralaterally (Figure 2A). Consistent with the in vitro data, castration of VCaP tumour-bearing mice resulted in a significant reduction in VCaP growth rate (Figure 2B) and serum PSA (Figure 2C). Co-inoculation of H295R cells significantly supported VCaP growth upon castration (+ADR→ORx) compared to VCaP growth in castrate animals without H295R (ORx) (Figure 2B). Despite the supportive effects of H295R on VCaP growth after castration, a clear castration response was still observed in the co-inoculated group, demonstrated by reduced growth rates compared to sham-castrated animals (- Figure 2B) and a reduction in serum PSA 1 week postorchiectomy (Figure 2C). Moreover, castration strongly reduced prostate and seminal vesicle weights in castrate animals, with no observed differences were between castrate animals with or without H295R, further demonstrating that H295R cells did not interfere with the systemic state of castration of the host animals (Figure S1).

A PSA rise from nadir was observed in 14/18 castrate animals concomitant with tumour growth, in castrate animals both with and without H295R (Figure 2D). Subsequent Abiraterone treatment at disease progression after castration had a significant impact on VCaP growth and PSA production, but only in castrate animals concomitantly bearing H295R tumours (Figure 2E-G and Figure S2), whilst we were unable to detect a significant difference in tumour growth or PSA production in castrate animals without H295R (ORx). Consistent with these results, in a parallel group of animals co-inoculated with H295R tumours at the time of castration, abiraterone was equally effective in reducing H295R-stimulated VCaP growth and PSA production (Figure S3). Of note, H295R growth was unaffected by castration or abiraterone treatment (Figure S4).

3.3 | Endocrine profiles in castration-and abiraterone-resistant VCaP xenografts

Levels of all steroids depicted in Figure 3A were investigated in tumour homogenates and plasma by LC-MS/MS. Testosterone was detectable in homogenates of four out of five VCaP tumours progressive under castration and coinoculated with H295R tumours. Surprisingly, testosterone could still be detected in homogenates of two out of five H295R-unsupported progressive VCaP tumours and three out of five abiraterone-treated sham-castrated VCaP tumours. One out of five castrate animals, but none of the abiraterone-treated intact animals, showed detectable testosterone plasma levels (Figure 3B). In plasma, DHEA was detectable in four out of five H295R-bearing animals, whilst in tumours, DHEA was found in four out of five placebo-treated H295R tumours and not in any VCaP tumour nor in any abiraterone-treated H295R tumour. Combined, these steroid levels suggest that testosterone found in H295R-supported VCaP tumours could be derived from DHEA secreted by H295R.
FIGURE 1 Adrenal steroids and tissue stimulate both castration-naive and castration-resistant prostate cancer. (A) Growth response of castration-naive VCaP and its CRPC derivatives (DCC-E, BIC-C, FLU-D) to androgen precursor steroids. Cells were cultured with physiological levels of 1.5 nM pregnenolone and 0.5 nM progesterone combined (PREC), 10 nM DHEA or 2.5 nM androstenedione (ADIONE), the combination of DHEA and ADION (ADRENAL) or 0.1 nM DHT and concomitantly treated with vehicle (DMSO), abiraterone (0.1 μM) or enzalutamide (1 μM). Bars represent mean fold over control (DCC/DMSO) ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Note: VCaP parental cells did not divide in castrate medium without steroids, whereas VCaP DCC-E, BIC-B and FLU-D divided by an average of threefold. (B) Human adrenal cells induce prostate cancer cell growth under castrate conditions in a two compartment cell culture system. Left: fold growth induction of VCaP parental cells by the human adrenal cell line H295R. Right: fold growth induction of VCaP DCC-E by H295R cells. Abiraterone reduced H295R-induced proliferation, but not basal proliferation in both prostate cancer cell lines. Bars represent mean ± SEM. VCaP parental n = 3, VCaP DCC-E n = 1. DMSO, dimethyl sulfoxide [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 (See caption on next page)
We further analysed mRNA expression for the key steroidogenic enzymes CYP11A1, CYP17A1, AKR1C3, and HSD17B6 (Figure 3A) in VCaP and H295R tumours. As expected, CYP11A1 mRNA was abundantly expressed in H295R while it was below the limit of detection for qPCR (ct > 40) in 14 out of 19 VCaP tumours (Figure 3C). CYP17A1 expression was detected in all VCaP tumours at a magnitude (on average: 1100 fold) lower than in H295R, with no alteration by castration or by abiraterone treatment. In contrast, AKR1C3 mRNA was abundantly expressed in VCaP and H295R tumours with slightly higher (fivefold) expression levels in H295R tumours. AKR1C3 expression in VCaP was higher in castrated than in noncastrated hosts, with no additional effect on expression levels by abiraterone treatment. HSD17B6 mRNA was detected in all VCaP tumours at levels above those found in H295R, with no effect of abiraterone treatment on expression levels.

We further evaluated serum levels of intermediates of the alternative androgen synthesis pathway. Although these intermediates accumulated upon blocking CYP17A1 with abiraterone (Figure 3D), this did not result in detectable intratumoural DHT levels (Figure 3B) nor did it result in measurable levels of CYP17A1-dependent downstream metabolites of the alternative androgen synthesis pathway (data not shown).

Finally, serum analysis revealed higher corticosterone levels in castrate animals, either with or without H295R tumours, regardless of abiraterone treatment (Figure 3E), suggesting increased glucocorticoid production in mice upon castration. Moreover, in castrate mice, CYP17A1-dependent 11-deoxycortisol could be detected, which was unaffected by treatment with abiraterone, except in H295R-bearing mice, where 11-deoxycortisol levels were significantly reduced by abiraterone.

3.4 Castration and abiraterone resistance is mediated via expression of ligand-independent AR (variants) and GR signalling

VCaP tumours progressively growing in castrate hosts showed higher mRNA expression levels of full length AR and AR variants (AR-V1 and AR-V7) as compared to VCaP tumours growing in sham-castrated animals, with no significant differences in expression level between abiraterone- and placebo-treated animals. In placebo-treated H295R-supported VCaP tumours, AR and AR variant expression was significantly higher compared to intact animals, but lower than in castrate hosts without H295R. This group, abiraterone significantly increased AR and AR-variant expression, similar to levels found in progressive VCaP tumours from castrate animals without H295R (Figure 4A).

PSA mRNA expression was similar for all VCaP tumours irrespective of H295R support and regardless of abiraterone treatment (Figure 4A).

Further analysis of AR target genes, such as FKBP5, TMPRSS2, TIPARP, and NDRG1, revealed no statistically significant differences between groups or treatments (Figure 4B), pointing towards restored AR signalling, despite limited detection of intratumoural testosterone and androgen synthesis intermediates in abiraterone-treated tumours. Moreover, expression of the AR target genes TMPRSS2, PSA and FKBP5 was correlated with increased expression of full length AR and AKR1C3, but not with increased expression of CYP17A1 (Figure 5).

In parallel with AR, GR expression was elevated in progressive H295R-un支持的 VCaP tumours compared to tumours grown in sham-castrated animals irrespective of abiraterone treatment. In H295R-supported VCaP tumours, abiraterone treatment increased GR expression (Figure 4C). Similarly, mRNA for the GR-regulated gene SGK1 could be detected in all VCaP tumours and was elevated in all castration-resistant and abiraterone-treated H295R-supported tumours, whilst remaining unaltered in the intact arm. Upregulation of GR was significantly correlated with the expression of SGK1 (Figure 4C). Subgroup analysis indicated that in VCaP tumours with increased expression of GR, SGK1 was only upregulated in castration-resistant tumours grown without H295R (open and closed red dots) and in abiraterone-treated tumours grown with H295R (purple filled dots) (Figure 4C).

Expression of AR and GR was further validated by immunohistochemistry. In noncastrate animals, AR staining in VCaP tumours was only nuclear. In castrated animals, both with and without H295R tumours, AR staining was intense and also cytoplasmatic, indicating these tumours were growing in an androgen-deprived environment (Figure 4D). Immunohistochemistry further

**FIGURE 2** In vivo prostate tumour growth is stimulated by the presence of a human adrenal xenograft, which can be reduced by CYP17A1 inhibition. (A) Flowchart of the in vivo experiment: VCaP tumours were inoculated with or without H295R tumours on the contralateral side. At progression after sham castration or castration, animals were randomised to receive daily oral gavage of abiraterone or placebo. (B) Mean relative growth ±95% CI of placebo treated animals from castration to humane endpoint. Growth rates were significantly lower in castrate than in intact animals, but no alteration by castration or by abiraterone treatment. Each bar represents an individual animal. (C) Waterfall plot of PSA response after operation, defined as % PSA change 1 week after sham castration or castration relative to serum PSA at time of operation. Each bar represents an individual animal. (D) Waterfall plot of PSA response at progression after operation, defined as % PSA change at progression after sham castration or castration relative to PSA nadir after operation. Each bar represents an individual animal. (E) Waterfall plot of PSA response after abiraterone treatment, defined as % PSA change after 1 week of abiraterone treatment relative to PSA at start of treatment. Each bar represents an individual animal. (F) Mean relative growth ±95% CI of placebo and abiraterone treated animals from start of treatment to humane endpoint, stratified by hormonal arm (intact, ORx, +ADT→ORx). Growth rates were only significantly different in the +ADT→ORx arm (students t-test p = 0.02) *p < 0.05. DT = tumour doubling time in days. (G) PSA levels (mean ± SEM) per treatment group, stratified by hormonal arm (intact, ORx, +ADT→ORx). Mann-Whitney test, *p < 0.05 **p < 0.01. CI, confidence interval [Color figure can be viewed at wileyonlinelibrary.com]
revealed that in progressive VCaP tumours under castrate conditions, GR localised to the nucleus, whereas GR protein was absent in VCaP tumours grown in sham-castrated hosts (Figure 4E).

4 | DISCUSSION

We developed a humanised murine model for CRPC to define the role of adrenal stimuli on progressive prostate cancer in castrated hosts. Physiological levels of adrenal steroids stimulated hormone-naïve and CRPC growth of VCaP cells, with no such effects induced by substrates of de novo steroid synthesis. The addition of human adrenal (H295R) cells to VCaP cultures and to VCaP-bearing mice stimulated VCaP growth upon androgen depletion. These stimulatory effects could be abolished by treatment with the CYP17A1 inhibitor abiraterone, while abiraterone could not reduce VCaP growth in the absence of human adrenal tissue. These observations together seem to suggest that VCaP tumours were not relying on CYP17A1-dependent, intratumoral de novo steroid synthesis for steroid-dependent AR-stimulus, but that an alternative means to stimulate
### FIGURE 4 (See caption on next page)

#### Table 1

| Gene   | Fold Change intact | Fold Change ORx | Fold Change +ADR → ORx | ANOVA |
|--------|--------------------|-----------------|------------------------|-------|
| AR-fl  | 1.00               | 0.88            | 24.33                  |       |
| AR-V1  | 1.00               | 1.08            | 121.92                 |       |
| AR-V7  | 1.00               | 0.62            | 132.70                 |       |
| PSA    | 1.00               | 1.16            | 1.00                   |       |
| FKBP5  | 1.00               | 1.90            | 0.74                   |       |
| TMPRSS2| 1.00               | 1.22            | 1.23                   |       |
| TIPARP | 1.00               | 1.10            | 1.06                   |       |
| NDRG1  | 1.00               | 1.58            | 1.80                   |       |
| GR     | 1.00               | 0.86            | 4.53                   |       |
| SGK1   | 1.00               | 0.72            | 4.17                   |       |

#### (A) AR²

#### (B) GR

#### (C) SGK1

#### (D) Androgen Receptor

#### (E) Glucocorticoid Receptor

---

The fold change values for each gene under different conditions are shown in the table. ANOVA results are also provided for statistical significance. The images (A) to (E) illustrate the expression of various genes under different treatments.
growth in the absence of androgens or androgen precursors existed. Steroid profiles in serum and tumour tissues confirmed that indeed both CYP17A1 substrate and CYP17A1 product were hardly detectable in VCaP tumours, whilst being abundant in plasma of tumour bearing mice and H295R tumours. Finally, AR variants and GR signalling were enhanced under abiraterone treatment, suggesting that prostate cancer switches from adrenal androgen dependency to androgen independent steroid receptors.

The supposed lack of adrenal CYP17A1 expression in rodents suggests lack of an androgen-pool in preclinical models that has proven to be highly relevant for prostate cancer progression in patients. To our surprise, we detected low testosterone serum levels in some, but not all castrate mice not engrafted with H295R. Also, CYP17A1-dependent 11-deoxycortisol was detected in all animals together with accumulating serum levels of CYP17A1 substrate progesterone in castrate mice treated with abiraterone. These data indicate that some 17-hydroxylase or 17,20 lyase activity must remain in castrate murine hosts, albeit without concomitant effects on castration-resistant VCaP tumour growth in our study. Potential sources of these steroids may be a partial switch of the adrenal gland to a testicular phenotype as reported in C57BL6-mice or the reported castration-induced development of adrenal tumours expressing gonadal markers in CE/J-mice. Recently, adrenal expression of CYP17A1 and detection of CYP17A1-dependent metabolites was demonstrated in CB-17 SCID mice. In our study, abiraterone did not affect castration-resistant VCaP growth in the absence of H295R, suggesting no relevant CYP17A1 dependent androgen synthesis in castrate NMRI mice.

In noncastrated hosts, abiraterone did not reduce plasma PSA levels or prostate or seminal vesicle size. These results may be explained by an excess of CYP17A1 in noncastrated animals, rendering abiraterone ineffective. An alternate explanation may be the reported reduced efficacy of abiraterone to inhibit murine CYP17A1 with abiraterone and abiraterone-acetate having an approx. 10-fold higher IC₅₀ in vitro for rodent CYP17A1 compared to human CYP17A1. This is supported by our observation that abiraterone reduced 11-deoxycortisol levels only in animals co-grafted with (human) H295R. Clearly, these interspecies differences in drug efficacy, alongside the aforementioned interstrain differences in enzyme expression, should be taken into account in further preclinical evaluation of novel steroid synthesis inhibitors and/or modelling of CRPC.

Figure 4

The rise in serum glucocorticoids in castrate animals corroborates previous reports that AR signalling potentiates the negative feedback by glucocorticoids on the hypothalamic-pituitary-adrenal (HPA) axis. How this HPA axis stimulation may affect CRPC growth remains to be explored, but increased levels of GR and GR signalling
have been reported in CRPC,\(^{18}\) enzalutamide-resistant disease\(^{19}\) and in abiraterone-resistant disease.\(^{20,22}\) This is of particular interest, as a clinical phase 2 abiraterone trial demonstrated superiority of concomitant administration of dexamethasone vs prednisone at a threefold lower equivalent daily glucocorticoid dose.\(^{27}\) On the contrary, in a post hoc analysis of the COU-AA-301 trial, corticosteroid use at baseline was associated with a worse overall prognosis, but not with less response to abiraterone.\(^{38}\) Clearly, further studies are warranted to investigate if targeting the GR in the setting of CRPC and abiraterone resistant prostate cancer may impair disease progression.

5 | CONCLUSIONS

We have established a humanised murine model for CRPC that mimics the endocrine environment in prostate cancer patients under ADT. We show that human adrenal tissue stimulates prostate cancer growth under castrate conditions. This model is highly responsive to treatment with the CYP17A1 inhibitor abiraterone, whilst tumours growing in absence of adrenal tissue are not. Resistant tumours show high levels of AR, AR variants, but also increased GR signalling, marking these as potential targets for treating abiraterone-resistant disease.

ACKNOWLEDGEMENTS

We thank A.H. Boer, D.C. Stuurman and S.A.H. Hoeben (Erasmus Medical Centre, Rotterdam, The Netherlands) for their assistance with the animal experiments. We would like to thank S. Blom and K. Valimaki (FIMM, Helsinki, Finland) for their technical support in constructing the tissue micro-array. The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115188, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

1. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11): 4447-4454.
2. Hofland J, van Weerden WM, Dits NF, et al. Evidence of limited contributions for intratumoral stereoidogenesis in prostate cancer. Cancer Res. 2010;70(3):1256-1264.
3. Luu-The V, Belanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab. 2008; 22(2):207-221.
4. Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71(20):6503-6513.
5. Mostaghel EA, Mark BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17(18):5913-5925.
6. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68(15): 6407-6415.
7. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005.
8. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66:815-825.
9. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13): 1187-1197.
10. Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(18):1755-1756.
11. Liu C, Lou W, Zhu Y, et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res. 2015;75(7):1413-1422.
12. Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012;97(2):507-516.
13. Moll JM, Kumagai J, van Royen ME, et al. A bypass mechanism of abiraterone-resistant prostate cancer: accumulating CYP17A1 substrates activate androgen receptor signaling. Prostate. 2019;79(9): 937-948.
14. Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6): 1273-1280.
15. Azad AA, Volik SV, Wyatt AW, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 2015;21(10):2315-2324.
16. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69(1):16-22.
17. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371(11):1028-1038.
18. Isikbay M, Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Hormones & Cancer. 2014;5(2):72-89.
19. Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309-1322.
20. Lam HM, McMullin R, Nguyen HM, et al. Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clin Cancer Res. 2017;23(9): 2301-2312.
21. van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schröder FH. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci. 1992;50(12):857-861.

22. Michiel Sedelaar JP, Dalrymple SS, Isaacs JT. Of mice and men—warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate. 2013;73(12):1316-1325.

23. Mostaghel EA, Zhang A, Hernandez S, et al. Contribution of adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer. Clin Cancer Res. 2019;25(1):426-439.

24. Bandiera R, Vidal VP, Motamedi FJ, et al. WT1 maintains adrenal-gonadal primordium identity and marks a population of AGP-like progenitors within the adrenal gland. Dev Cell. 2013;27(1):5-18.

25. van der Pas R, Hofland LJ, Hofland J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012;215(3):403-412.

26. Bélanger A, Candas B, Dupont A, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab. 1994;79(4):1086-1090.

27. Taplin ME, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32(33):3705-3715.

28. Kumagai J, Hofland J, Erkens-Schulze S, et al. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis. Prostate. 2013;73(15):1636-1650.

29. Haring R, Wallaschofski H, Teumer A, et al. A SULT2A1 genetic variant identified by GWAS as associated with low serum DHEAS does not impact on the actual DHEA/DHEAS ratio. J Mol Endocrinol. 2013;50(1):73-77.

30. Jühen R, Idkowski J, Taylor AE, et al. Role of ALADIN in human adrenocortical cells for oxidative stress response and steroidogenesis. PLoS One. 2015;10(4):e0124582.

31. van Soest RJ, van Royen ME, de Morré ES, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer. 2013;49(18):3821-3830.

32. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004;25(6):947-970.

33. Johnsen IK, Slawik M, Shapiro I, et al. Gonadectomy in mice of the inbred strain CE/J induces proliferation of sub-capsular adrenal cells expressing gonad marker genes. J Endocrinol. 2006;190(1):47-57.

34. Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol. 2003;84(5):555-562.

35. Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC. NF-kappaB2/p52:cbeta2/p52:cMyc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther. 2015;14:1884-1895.

36. Chen CV, Brummet JL, Lonstein JS, Jordan CL, Breedlove SM. New knockout model confirms a role for androgen receptors in regulating anxiety-like behaviors and HPA response in mice. Horm Behav. 2014;65(3):211-218.

37. Lorente D, Omlin A, Ferraldeschi R, et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer. 2014;111(12):2248-2253.

38. Montgomery B, Kheoh T, Molina A, et al. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. 2015;67(5):866-873.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher's website.